Companisto • GROWNVALVE
Equity crowdfunding
GROWNVALVE
Lifelong cure for heart valve defects. EU-funded medtech startup develops growing implants made from the patient’s own tissue.
Key project data
Target amount
2.85 MEUR
Valuations
18.0 MEUR
Potential Returns
548%
Expected Exit Year
2030
Would AI invest?
69/100
1
100
AI-Generated Overview
AI project overview
Condensed summary based on project data
<h1><span style="font-size:16pt"><span style="font-family:"Times New Roman",serif"><span style="color:#2e74b5"><em>GrOwnValve GmbH</em> — Crowdfunding Investor Memo</span></span></span></h1> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><em>A regenerative, autologous transcatheter heart valve made from the patient's own pericardial tissue — for adults and, prospectively, children.</em></span></span></p> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Sector: <strong><em>MedTech — structural heart (MDR Class III)</em></strong> · Stage: <strong><em>Seed</em></strong> · HQ: <strong><em>Berlin, Germany</em></strong> · Raise: <strong><em>~€1.5M open on Companisto (within €6.2M tranche; see Red Flag 2)</em></strong></span></span></p> <table border="0" cellspacing="0" class="Table" style="border-collapse:collapse; border-color:currentcolor; border-image:initial; border-style:none; border-width:medium"> <tbody> <tr> <td style="background-color:#faeeda; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; width:213px"><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">AI SCORE</span></strong></span></span></td> <td style="background-color:#faeeda; border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:411px"><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Why this score:</span></strong></span></span></td> </tr> <tr> <td style="background-color:#faeeda; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; width:213px"> <p style="text-align:center"><span style="font-size:26px"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">69 </span></strong></span></span><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black"><strong><em><span style="font-family:"Nova Mono"">⭐ Moderate</span></em></strong></span></span></span></p> </td> <td style="background-color:#faeeda; border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:411px"> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><em><span style="color:black">Strong clinical-research anchoring at Charité/DHZC — Europe's leading structural-heart centre — with CTO and COO bringing 50+ years of medtech operating experience.</span></em></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><em><span style="color:black">TAVR market of $10–14B by 2030 confirmed across multiple independent analysts; pediatric pulmonary TPVR market a smaller €118M.</span></em></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><em><span style="color:black">Only 4–5 human patients implanted and follow-up under 12 months for most; durability thesis not yet clinically validated at scale.</span></em></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><em><span style="color:black">About 3.5 years to broad market approval per the company's own SWOT; two further financing rounds explicitly planned.</span></em></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><em><span style="color:black">Material disclosure gaps — liquidation preference, drag-along threshold, anti-dilution provisions and EIB instrument structure all absent from the materials; round-size figures inconsistent across deck and investor call.</span></em></span></span></li> </ul> </td> </tr> </tbody> </table> <p> </p> <table cellspacing="0" class="Table" style="border-collapse:collapse; border-color:currentcolor; border-image:initial; border-style:none; border-width:medium"> <tbody> <tr> <td style="background-color:#e6f1fb; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:624px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">ℹ️ This is not investment advice. </span></strong><span style="color:black">The purpose of this overview is to help potential investors preselect crowdfunding projects quickly. Before investing, the final selected project should be reviewed in detail based on the information provided by the company on the respective crowdfunding platform, and you may want to seek independent professional advice.</span></span></span></p> </td> </tr> </tbody> </table> <h2><span style="font-size:13pt"><span style="font-family:"Times New Roman",serif"><span style="color:#2e74b5">🏢 Company description</span></span></span></h2> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">GrOwnValve develops a transcatheter heart-valve prosthesis built from the patient's own pericardial tissue. The valve is fabricated in the operating room during a single procedure: CT or MRI data drives a 3D-printed patient-specific mould, pericardial tissue is harvested via a small thoracotomy, shaped over the mould, treated with the company's proprietary glutaraldehyde-free crosslinker, sutured onto a stent, and implanted via catheter. The clinical proposition the company reports is that an autologous valve avoids the calcification, immune-rejection and lifelong-anticoagulation drawbacks of mechanical and animal-tissue prostheses, can grow with a pediatric patient, and ideally lasts a lifetime.</span></span></p> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">The company is a 2019 spin-off from the German Heart Center and Charité in Berlin, founded by PD Dr. Boris Schmitt (pediatric cardiologist, inventor and CEO/CMO) and Jasper Emeis (CFO). It is currently running its first-in-human GECT-DZHK28 feasibility study at Charité in adult patients, with 4–5 of 7 planned implants completed and the remainder scheduled for Q1–Q2 2026. The product portfolio is designed as a procedure-pack platform addressing pulmonary valves first (including a pediatric variant with a bioresorbable stent, still in development) and aortic valves second (at proof-of-concept stage).</span></span></p> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">The company reports three revenue streams once approved: procedure-pack sales (the main product, MDR Class III), on-site service in the operating room, and physician training and licensing. Cost of goods sold is stated at approximately €1,000 per pack versus sale prices of €8,000–€16,000 for incumbent animal-tissue valves; final pricing is not disclosed. The current Companisto round is intended to fund continued clinical study (GECT continuation in adolescents), design freeze of the pulmonary device, and proof-of-concept work for the aortic programme. Final CE and FDA approvals are targeted for 2030.</span></span></p> <h2><span style="font-size:13pt"><span style="font-family:"Times New Roman",serif"><span style="color:#2e74b5">🎯 Target returns </span></span></span></h2> <table cellspacing="0" class="Table" style="border-collapse:collapse; border-color:currentcolor; border-image:initial; border-style:none; border-width:medium"> <thead> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:156px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Target return</span></strong></span></span></p> </td> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:156px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Time horizon</span></strong></span></span></p> </td> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:156px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Target basis</span></strong></span></span></p> </td> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:156px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">AI view on reaching this goal</span></strong></span></span></p> </td> </tr> </thead> <tbody> <tr> <td style="border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:156px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><em>🎯 ~6.5x (~52% p.a.)</em></strong></span></span></p> </td> <td style="border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:156px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><em><span style="font-family:Cardo">⏱ 4–5 years</span></em></strong></span></span></p> </td> <td style="border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:156px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong>Mixed</strong> — Companisto computed the headline return from its own valuation work using inputs (financial projections, reference transactions, exit narrative) provided by the company.</span></span></p> </td> <td style="border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:156px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Plausible but binary: requires positive pivotal-trial data plus a strategic acquisition at roughly $300M or above within the 4–5 year window, both materially uncertain.</span></span></p> </td> </tr> </tbody> </table> <p> </p> <h3><span style="font-size:12pt"><span style="font-family:"Times New Roman",serif"><span style="color:#1f4d78">📈 Path to target return</span></span></span></h3> <table cellspacing="0" class="Table" style="border-collapse:collapse; border-color:currentcolor; border-image:initial; border-style:none; border-width:medium"> <tbody> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:200px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Sector heuristic</span></strong></span></span></p> </td> <td style="border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:424px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">MDR Class III regenerative medtech at first-in-human-feasibility stage typically reaches a 10x outcome through either (a) strategic acquisition by a top-3 structural-heart incumbent following positive pivotal-trial data, or (b) IPO after CE/FDA approval; both routes presume 4–7 further years of capital and clinical execution.</span></span></p> </td> </tr> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:200px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Current key metric</span></strong></span></span></p> </td> <td style="border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:424px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">4–5 of 7 first-in-human patients implanted as of April–May 2026 (the figure varies across the company's own materials); positive echo follow-up across all patients to date. ISO 13485 certified end-2025. €5.5M+ in non-dilutive EU funding secured.</span></span></p> </td> </tr> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:200px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Required scale at exit</span></strong></span></span></p> </td> <td style="border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:424px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Per the company's cited reference transactions (Cardioband 2017, Symetis 2017, Millipede 2018, Claret 2018, CardioValve 2021, Innovalve 2024, JenaValve 2024, JC Medical 2024) structural-heart M&A in this segment has settled in the range of approximately $300M to $435M+ when targets reach late-stage clinical or early-commercial maturity. Note that the JenaValve transaction is under FTC challenge as of August 2025.</span></span></p> </td> </tr> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:200px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Implied IRR</span></strong></span></span></p> </td> <td style="border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:424px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">An exit at approximately €100M in 5 years implies roughly 41% per year gross to today's investors before liquidation-preference adjustments and dilution from the two further rounds the company has stated it intends to raise. An exit at approximately €300M in 5 years implies roughly 75% per year on the same simplifying assumptions; the 52% per year platform target sits between these.</span></span></p> </td> </tr> </tbody> </table> <h2><span style="font-size:13pt"><span style="font-family:"Times New Roman",serif"><span style="color:#2e74b5">💶 Valuation</span></span></span></h2> <table cellspacing="0" class="Table" style="border-collapse:collapse; border:none; width:624px"> <tbody> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:200px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Pre-money valuation</span></strong></span></span></p> </td> <td style="border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:424px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">€18.0 million</span></span></p> </td> </tr> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:200px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Post-money valuation</span></strong></span></span></p> </td> <td style="border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:424px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Approximately €19.6M if the smaller round figure (€1.6M Companisto tranche) is correct — this reconciles to the disclosed 8.19% Companisto pool share. Approximately €30M if the larger figure (€12M total round) is correct. The two are not reconciled in the provided materials (see Red Flag 2).</span></span></p> </td> </tr> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:200px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Instrument</span></strong></span></span></p> </td> <td style="border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:424px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Profit-participating certificate (Gewinnbeteiligungs- or Genussrecht), pooled via Companisto's collective vehicle. Not direct equity. Minimum investment €250. Contract term 7–8 years, illiquid until sale/IPO.</span></span></p> </td> </tr> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:200px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">How the valuation was set</span></strong></span></span></p> </td> <td style="border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:424px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Stated methodology: "derived from past M&A activities," supported by a list of 10 reference transactions in structural-heart medtech (2017–2024) with purchase prices from $72M to $435M+. No DCF, no revenue multiple, no comparable-stage benchmarking shown. The €18M pre-money reconciles mathematically to the disclosed cap-table arithmetic under the smaller round figure.</span></span></p> </td> </tr> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:200px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">External benchmarks</span></strong></span></span></p> </td> <td style="border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:424px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Pre-money of €18M for a clinical-feasibility-stage medtech with €5.5M+ in grants secured, an active first-in-human trial, ISO 13485, and a granted US patent is within the plausible range for European structural-heart seed deals, though on the higher side of the median for stage. The premium reflects the company's clinical traction and the size of the addressable market, not commercial traction.</span></span></p> </td> </tr> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:200px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Notable terms</span></strong></span></span></p> </td> <td style="border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:424px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Subordinated participation right behind any senior preferences (which are not disclosed). Voting rights are indirect via Companisto's pooling structure — individual investors do not vote on company matters. No anti-dilution protection. No pre-emption rights typical for this instrument.</span></span></p> </td> </tr> </tbody> </table> <p> </p> <h2><span style="font-size:13pt"><span style="font-family:"Times New Roman",serif"><span style="color:#2e74b5">📜 Instrument & investor terms</span></span></span></h2> <h3><span style="font-size:12pt"><span style="font-family:"Times New Roman",serif"><span style="color:#1f4d78">What you own</span></span></span></h3> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">The instrument is a profit-participating certificate (Gewinnbeteiligungs- or Genussrecht), not a direct equity share. This is Companisto's standard subordinated participation structure: economically, the holder is entitled to a pro-rata share of the company's profits and exit proceeds once any senior claims and liabilities have been paid. Investors are pooled via Companisto's collective vehicle — you do not become a direct shareholder of GrOwnValve GmbH. Voting rights are indirect: individual investors do not vote on company matters, and votes attached to the pooled stake are exercised collectively through Companisto's pooling structure. The decision to sell the company — the event that determines whether and when investors see any return — will be made by the founders and senior shareholders, not by the crowdfund pool. Minimum investment €250.</span></span></p> <h3><span style="font-size:12pt"><span style="font-family:"Times New Roman",serif"><span style="color:#1f4d78">Dilution and future rounds</span></span></span></h3> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">The company has explicitly stated intention to raise two further financing rounds before approval; a Series A is described as in preparation with four venture-capital investors named (collectively, not by name) as being in pre-due-diligence or term-sheet conversations. Crowdfund investors typically do not hold anti-dilution protection on this instrument. Whether earlier classes (existing angel investors and the EIB tranche) hold anti-dilution protection is not disclosed.</span></span></p> <p style="text-align:justify"><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Worked example, using standard cap-table mechanics on the disclosed €18M pre-money valuation and the smaller round figure (€1.6M new capital, which reconciles to the 8.19% Companisto pool share). If you invest €1,000 today at an effective post-money of approximately €19.6M, your economic exposure is roughly 0.0051% of the company — about five basis points. If GrOwnValve then raises a Series A of €5M at a €40M pre-money valuation (a successful up-round), the new post-money is €45M and your effective stake dilutes by 11% to approximately 0.0045%; on a pari-passu basis the implied value of your investment is roughly €2,025, a 2.0x gross markup. If instead the next round is priced lower — a down-round of €3M at €10M pre-money, post-money €13M — your stake dilutes by 23% to approximately 0.0039% and the implied value of your investment falls to roughly €510, a loss of about 49%. These figures assume pari-passu treatment and ignore any liquidation preferences earlier investors may hold; if such preferences exist, the actual outcome for the crowdfund pool in either scenario would be worse.</span></span></p> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Employee stock option pool (ESOP) size and any planned expansion are not disclosed. Pre-emption rights — whether crowdfund investors can participate in future rounds to defend their percentage — are not disclosed and are typically absent from Companisto-style pooled participation rights.</span></span></p> <h3><span style="font-size:12pt"><span style="font-family:"Times New Roman",serif"><span style="color:#1f4d78">Exit and liquidation mechanics</span></span></span></h3> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Liquidation preference order and multiple are not disclosed in the provided materials. In a sale at or below the current €18M valuation, the order of payouts (creditors first, then any preferred classes, then ordinary shareholders, then the crowdfund pool) determines who receives what. Without disclosure, you cannot assess whether the EIB tranche (€3.1M to €5.3M), the angel convertible loan agreement (€1.6M to €2.2M), or any prior preferred share class sits ahead of the Companisto pool in the queue. In a strong exit well above current valuation this matters less; in a moderate or weak exit it can mean crowdfund investors receive little or nothing.</span></span></p> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Drag-along threshold (the percentage of shareholders who can force everyone else to sell on the same terms) and tag-along rights (the right to join a sale on the same terms as the seller) are not disclosed. As a general matter for this instrument: founders and senior shareholders, who together hold approximately 91.8% post-round, can almost certainly act on a strategic sale without the crowdfund pool's consent.</span></span></p> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Lock-up period and secondary-market availability: Companisto's standard contract runs 7–8 years with no secondary market on the platform. Investors should treat this position as fully illiquid until a strategic exit or IPO. If the company's stated timeline holds, this means realistically waiting until approximately 2029–2031 for any return event.</span></span></p> <h3><span style="font-size:12pt"><span style="font-family:"Times New Roman",serif"><span style="color:#1f4d78">Key risks specific to this instrument</span></span></span></h3> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">No individual voting rights — investors cannot influence the company's decisions, including the decision to sell, the timing of the sale or the terms accepted.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Liquidation-preference order not disclosed — in an exit at or below current valuation, the crowdfund pool may receive little or nothing after creditors, the EIB tranche and any senior preferred holders are paid.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Anti-dilution protection probably absent for crowdfund investors — if the company raises a down-round to bridge to approval, dilution falls disproportionately on the crowdfund pool relative to any class that does hold ratchet protection.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Drag-along terms not disclosed — founders and senior shareholders, holding ~91.8% post-round, can almost certainly force a sale on terms set without crowdfund-pool input.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">No secondary market — the position is illiquid until a strategic exit or IPO, realistically 2029 at the earliest on the company's own roadmap.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Two further financing rounds explicitly planned before approval — crowdfund investors cannot participate pro-rata to defend their percentage; dilution from these rounds is essentially certain.</span></span></span></li> </ul> <h3><span style="font-size:12pt"><span style="font-family:"Times New Roman",serif"><span style="color:#1f4d78">Items not disclosed</span></span></span></h3> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Absence of disclosure on any of the following means the investor cannot assess these terms before investing:</span></span></p> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Liquidation-preference multiple (1x, 1.5x, 2x) and whether participating or non-participating.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Order of liquidation preference relative to the EIB tranche, the angel convertible loan agreement and any prior preferred classes.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Drag-along threshold percentage.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Tag-along rights.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Founder vesting schedule.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Anti-dilution provisions for any class of shareholder.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Detailed pre-round capitalisation table — only post-round percentages are disclosed.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">ESOP size and any planned expansion.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Information rights — frequency and content of investor reporting between investment and exit.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Conversion terms (cap, discount, trigger) of the angel convertible loan agreement worth €1.6M to €2.2M.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">EIB instrument structure — whether the €3.1M to €5.3M EIB tranche is equity, debt or quasi-equity.</span></span></span></li> </ul> <p> </p> <h2><span style="font-size:13pt"><span style="font-family:"Times New Roman",serif"><span style="color:#2e74b5">📊 Score breakdown</span></span></span></h2> <table cellspacing="0" class="Table" style="border-collapse:collapse; border-color:currentcolor; border-image:initial; border-style:none; border-width:medium"> <thead> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:160px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Category</span></strong></span></span></p> </td> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:73px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Score</span></strong></span></span></p> </td> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:73px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Weight</span></strong></span></span></p> </td> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:317px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Verdict & key reason</span></strong></span></span></p> </td> </tr> </thead> <tbody> <tr> <td style="border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:160px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong>Team</strong></span></span></p> </td> <td style="background-color:#d9ebc2; border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:73px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">82</span></strong></span></span></p> </td> <td style="border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:73px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">18%</span></span></p> </td> <td style="background-color:#d9ebc2; border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:317px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Strong</span></strong><span style="color:black"> — Founder/CMO is the inventor and a working pediatric cardiologist at Charité/DHZC; CTO and COO bring combined ~50 years of medtech operating experience (Abbott, BIOTRONIK, Xeltis, Medtronic CoreValve).</span></span></span></p> </td> </tr> <tr> <td style="border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:160px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong>Product–Market Fit</strong></span></span></p> </td> <td style="background-color:#faeeda; border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:73px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">65</span></strong></span></span></p> </td> <td style="border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:73px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">15%</span></span></p> </td> <td style="background-color:#faeeda; border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:317px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Moderate</span></strong><span style="color:black"> — Clinical need is unambiguous and early data uniformly positive, but only 4–5 patients implanted and follow-up under 12 months for most; pediatric positioning runs ahead of pediatric clinical data.</span></span></span></p> </td> </tr> <tr> <td style="border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:160px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong>Traction</strong></span></span></p> </td> <td style="background-color:#faeeda; border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:73px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">60</span></strong></span></span></p> </td> <td style="border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:73px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">15%</span></span></p> </td> <td style="background-color:#faeeda; border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:317px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Moderate</span></strong><span style="color:black"> — Pre-revenue by design; €5.5M+ non-dilutive grant funding and active first-in-human trial are real, but commercial traction does not yet exist (capped at LIMITED ceiling of 70).</span></span></span></p> </td> </tr> <tr> <td style="border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:160px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong>Market</strong></span></span></p> </td> <td style="background-color:#d9ebc2; border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:73px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">85</span></strong></span></span></p> </td> <td style="border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:73px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">11%</span></span></p> </td> <td style="background-color:#d9ebc2; border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:317px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Strong</span></strong><span style="color:black"> — Global TAVR market of $10B+ by 2030 confirmed independently by Grand View Research, Mordor Intelligence and other analysts; valve-in-valve sub-segment growing 15% per year.</span></span></span></p> </td> </tr> <tr> <td style="border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:160px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong>Business model</strong></span></span></p> </td> <td style="background-color:#faeeda; border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:73px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">62</span></strong></span></span></p> </td> <td style="border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:73px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">7%</span></span></p> </td> <td style="background-color:#faeeda; border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:317px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Moderate</span></strong><span style="color:black"> — Three revenue streams articulated and cost advantage is large (~€1,000 COGS vs €8,000–16,000 sale price for animal-tissue valves); pricing not finalised and 2030 ramp is optimistic.</span></span></span></p> </td> </tr> <tr> <td style="border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:160px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong>Competition</strong></span></span></p> </td> <td style="background-color:#faeeda; border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:73px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">65</span></strong></span></span></p> </td> <td style="border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:73px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">7%</span></span></p> </td> <td style="background-color:#faeeda; border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:317px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Moderate</span></strong><span style="color:black"> — Direct competitors (Medtronic Melody/Harmony, Edwards SAPIEN 3) accurately profiled; regenerative-tissue competitors (Xeltis, Ozaki) omitted from deck; one US patent granted, others pending.</span></span></span></p> </td> </tr> <tr> <td style="border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:160px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong>Compliance / Regulatory</strong></span></span></p> </td> <td style="background-color:#faeeda; border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:73px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">60</span></strong></span></span></p> </td> <td style="border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:73px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">12%</span></span></p> </td> <td style="background-color:#faeeda; border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:317px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Moderate</span></strong><span style="color:black"> — ISO 13485 complete; BfArM has confirmed MDR Class III pathway; FDA dialogue ongoing with possible Breakthrough Device Designation. About 3.5 years to broad approval.</span></span></span></p> </td> </tr> <tr> <td style="border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:160px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong>Technology risk</strong></span></span></p> </td> <td style="background-color:#faeeda; border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:73px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">65</span></strong></span></span></p> </td> <td style="border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:73px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">15%</span></span></p> </td> <td style="background-color:#faeeda; border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:317px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Moderate</span></strong><span style="color:black"> — 21-month sheep follow-up shows no calcification, no degeneration, complete endothelialization; operator-dependent in-OR assembly and 200× volume scaling to 2030 projection remain open questions.</span></span></span></p> </td> </tr> </tbody> </table> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong>Why these weights? </strong>The default seed-stage weighting (Team 25, PMF 20, Traction 20, Market 15, Business model 10, Competition 10) was adjusted for this deal's sector profile by adding two categories — Compliance / Regulatory (12 points, because the device is MDR Class III with binary approval risk) and Technology risk (15 points, because the device is deeptech with novel autologous-tissue mechanics and an unproven point-of-care manufacturing model). The 27 added weight points were taken pro-rata from the six default categories (a 0.73 scaling factor applied). The result places the highest weight on Team (18%) and Technology risk (15%) — the two factors that most determine whether GrOwnValve can execute the long bridge to approval. Traction remains weighted at 15% despite being LIMITED data quality, because pre-revenue is structural to the stage rather than a company-specific weakness; the LIMITED cap of 70 prevents the score from inflating regardless. No category was scored N/A, so no weight redistribution was required. All weights sum to exactly 100.</span></span></p> <p> </p> <h2><span style="font-size:13pt"><span style="font-family:"Times New Roman",serif"><span style="color:#2e74b5">🔍 Detailed review</span></span></span></h2> <h3><span style="font-size:12pt"><span style="font-family:"Times New Roman",serif"><span style="color:#1f4d78">Team capability</span></span></span></h3> <table cellspacing="0" class="Table" style="border-collapse:collapse; border-color:currentcolor; border-image:initial; border-style:none; border-width:medium"> <tbody> <tr> <td style="background-color:#d9ebc2; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:624px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Score 82 of 100</span></strong><span style="color:black"> — Strong. Data quality: STRONG.</span></span></span></p> </td> </tr> </tbody> </table> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">The CEO/CMO is the inventor of the technology and remains a working pediatric cardiologist at the German Heart Center / Charité, one of Europe's leading cardiac centres. The CTO (Boris Warnack) brings over 30 years of medtech operating experience including programme leadership of the first bioresorbable stent at a ~250-person global team, with past employers Abbott, BIOTRONIK and Xeltis. The COO (Benjamin Rieck) reports involvement in CoreValve (the original TAVI valve, acquired by Medtronic). ISO 13485 certification was completed at the end of 2025.</span></span></p> <table cellspacing="0" class="Table" style="border-collapse:collapse; border-color:currentcolor; border-image:initial; border-style:none; border-width:medium"> <thead> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:312px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black"><strong><span style="font-family:"Arial Unicode MS"">✅ Strengths</span></strong></span></span></span></p> </td> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:312px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">⚠️ Gaps</span></strong></span></span></p> </td> </tr> </thead> <tbody> <tr> <td style="border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:312px"> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">PD Dr. Boris Schmitt (CEO/CMO) is the inventor of the technology with 20+ years of pediatric and interventional cardiology experience at Charité and DHZC; habilitation completed; independently verifiable across BIH, DZHK and peer-reviewed publications.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">CTO Boris Warnack has 30+ years of medtech industrial experience including bioresorbable-stent programme leadership; past employers include Abbott, BIOTRONIK, Xeltis and Gambro.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">COO Benjamin Rieck has the original CoreValve TAVI valve on his operating CV — the literal predecessor of the market this company plans to enter.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Medical Advisory Board includes Prof. Frank Edelmann (Principal Investigator of the active GECT-DZHK28 trial, confirmed on ClinicalTrials.gov), Prof. Felix Berger (Head of Pediatric Cardiology at Charité/DHZC) and Dr. Peter Kramer.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">ISO 13485 certification — a non-trivial operational achievement for a 15–22 person company — was completed at end-2025.</span></span></span></li> </ul> </td> <td style="border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:312px"> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Founder concentration risk: Boris Schmitt holds CEO and CMO simultaneously while remaining clinically active at Charité; no succession plan is disclosed.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">No CFO with controlling background is currently on the team — flagged in the company's own use-of-funds section as a near-term hire.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">The deck claim of "more than 20 exits" for COO Rieck is not independently verifiable in the provided materials.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Team-size figures are inconsistent across the same package: 15 (analysis), 18 (deck team slide) and 22 (deck overview slide).</span></span></span></li> </ul> </td> </tr> </tbody> </table> <h3><span style="font-size:12pt"><span style="font-family:"Times New Roman",serif"><span style="color:#1f4d78">Product–Market Fit</span></span></span></h3> <table cellspacing="0" class="Table" style="border-collapse:collapse; border-color:currentcolor; border-image:initial; border-style:none; border-width:medium"> <tbody> <tr> <td style="background-color:#faeeda; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:624px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Score 65 of 100</span></strong><span style="color:black"> — Moderate. Data quality: MODERATE.</span></span></span></p> </td> </tr> </tbody> </table> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">The clinical problem is unambiguous: the company reports that approximately 400,000 babies per year need a pediatric heart valve and that no pediatric-specific valve exists on the market; for adults, valve degeneration and re-do cycles are well-evidenced and growing. Early human data is uniformly positive at the echo endpoint across all implanted patients, with three patients now reportedly carrying the valve for more than 12 months. The 21-month sheep follow-up published in Catheterization and Cardiovascular Interventions (Kiekenap et al. 2024) is unusually strong preclinical evidence. The primary durability and regeneration thesis has not yet been clinically validated at scale.</span></span></p> <table cellspacing="0" class="Table" style="border-collapse:collapse; border-color:currentcolor; border-image:initial; border-style:none; border-width:medium"> <thead> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:312px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black"><strong><span style="font-family:"Arial Unicode MS"">✅ Strengths</span></strong></span></span></span></p> </td> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:312px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">⚠️ Risks</span></strong></span></span></p> </td> </tr> </thead> <tbody> <tr> <td style="border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:312px"> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Clinical need is unambiguous and well-evidenced: 1/8 adults will need a valve replacement; 400,000 babies per year urgently need a valve worldwide.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Early human data is uniformly positive at the echo endpoint across all implanted patients; three patients now carry the valve for more than 12 months.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">21-month sheep follow-up in 29 animals shows no calcification, no degeneration, no stenosis and complete endothelialization — published in a peer-reviewed cardiology journal.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Patient-pull anecdotes exist (a 34-year-old construction worker who chose GrOwnValve over a mechanical valve; a 35-year-old who hiked the Machu Picchu trail three months post-procedure).</span></span></span></li> </ul> </td> <td style="border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:312px"> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Total human-patient sample is 4–5 (the figure conflicts across materials) within a single-site feasibility study at Charité; the primary durability thesis has not been clinically validated at scale.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Most patient follow-up is currently under 12 months — well below the 5-year window that would confirm or refute the lifelong-valve thesis.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Pediatric positioning in marketing materials runs ahead of the pediatric clinical data: the first-in-human study is in adults, and the first pediatric study is not planned until 2028–2029.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Adoption decisions in this segment rest with heart teams, hospital purchasing and reimbursement coding — patient pull does not translate directly into commercial PMF.</span></span></span></li> </ul> </td> </tr> </tbody> </table> <h3><span style="font-size:12pt"><span style="font-family:"Times New Roman",serif"><span style="color:#1f4d78">Traction</span></span></span></h3> <table cellspacing="0" class="Table" style="border-collapse:collapse; border-color:currentcolor; border-image:initial; border-style:none; border-width:medium"> <tbody> <tr> <td style="background-color:#faeeda; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:624px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Score 60 of 100</span></strong><span style="color:black"> — Moderate. Data quality: LIMITED.</span></span></span></p> </td> </tr> </tbody> </table> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">GrOwnValve has no commercial revenue, which is structural to the stage rather than a company-specific weakness — pre-approval medtech does not bill into payers. Where traction does exist, it is real: total funding since the 2019 spin-off is reported by DZHK at €7.8M, of which the company describes €5.5M+ as non-dilutive EU and federal grants (EIC Accelerator €3.1M, EIC Transition €2.5M, plus various BMBF and Spark programmes). The GECT-DZHK28 clinical trial is active and recruiting per ClinicalTrials.gov.</span></span></p> <table cellspacing="0" class="Table" style="border-collapse:collapse; border-color:currentcolor; border-image:initial; border-style:none; border-width:medium"> <thead> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:312px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black"><strong><span style="font-family:"Arial Unicode MS"">✅ Strengths</span></strong></span></span></span></p> </td> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:312px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">⚠️ Gaps</span></strong></span></span></p> </td> </tr> </thead> <tbody> <tr> <td style="border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:312px"> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Non-dilutive grant traction is strong: €5.5M+ in EU and federal funding (EIC Accelerator €3.1M, EIC Transition €2.5M, plus exist, Spark and BMBF programmes); DZHK reports €7.8M total since 2019.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">GECT-DZHK28 first-in-human trial confirmed active and recruiting on ClinicalTrials.gov (NCT05809856); start date December 2023; primary completion estimated January 2031.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Publication record spans Science Translational Medicine, EuroIntervention, European Heart Journal and Catheterization and Cardiovascular Interventions; conference presence at TCT, MedTech Innovator and LSI.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Regulatory dialogue is open with both BfArM (Germany) and the FDA (United States), with Breakthrough Device Designation pathway in active discussion.</span></span></span></li> </ul> </td> <td style="border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:312px"> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Zero commercial revenue, by design — pre-approval status caps the score at the LIMITED data-quality ceiling of 70.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Series A is described as in preparation with four VCs in pre-DD or term-sheet conversations, but no investors are named.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Disclosed round size is internally inconsistent across materials (€12M / €4.5M open in the deck versus €6.2M / €1.5M open in the investor call) — a traction-disclosure problem that erodes confidence in the rest of the package.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Total funding figures (€5.5M+, €7.8M, €8M) appear in different forms across materials and roughly but not exactly reconcile.</span></span></span></li> </ul> </td> </tr> </tbody> </table> <h3><span style="font-size:12pt"><span style="font-family:"Times New Roman",serif"><span style="color:#1f4d78">Market</span></span></span></h3> <table cellspacing="0" class="Table" style="border-collapse:collapse; border-color:currentcolor; border-image:initial; border-style:none; border-width:medium"> <tbody> <tr> <td style="background-color:#d9ebc2; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:624px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Score 85 of 100</span></strong><span style="color:black"> — Strong. Data quality: STRONG.</span></span></span></p> </td> </tr> </tbody> </table> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">The global TAVR market is the prize: independently estimated at $10.2B–$10.5B by 2030 by Grand View Research and Mordor Intelligence with growth rates of 7–10% per year, and at $13.4B by Strategic Market Research. The valve-in-valve sub-segment is projected to grow from 10k procedures in 2025 to 42k by 2035 — a structural-replacement-cycle tailwind that directly benefits a longer-lasting valve. The pediatric pulmonary TPVR market is meaningfully smaller (€118M by 2030) but is the company's first commercial entry point.</span></span></p> <table cellspacing="0" class="Table" style="border-collapse:collapse; border-color:currentcolor; border-image:initial; border-style:none; border-width:medium"> <thead> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:312px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black"><strong><span style="font-family:"Arial Unicode MS"">✅ Strengths</span></strong></span></span></span></p> </td> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:312px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">⚠️ Risks</span></strong></span></span></p> </td> </tr> </thead> <tbody> <tr> <td style="border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:312px"> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Global TAVR market of $10.2B–$10.5B by 2030 is confirmed independently by Grand View Research, Mordor Intelligence and other analysts — multi-source convergence.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Valve-in-valve sub-segment growing from 10k procedures in 2025 to 42k by 2035 (15% CAGR) creates a durable structural-replacement-cycle tailwind.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Patient pool figures are large and well-evidenced: 4.6M adults globally currently in need of a valve; 350k treated per year; 1.4M babies per year with congenital heart defects.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Existing DRG/OPS reimbursement codes (TAVR F02A €27,300 / F02C €15,600; TPVR F03A €26,500 / F03C €14,820 in Germany) mean GrOwnValve can plausibly bill into existing pathways from day one of approval.</span></span></span></li> </ul> </td> <td style="border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:312px"> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Pediatric pulmonary TPVR market is genuinely small (~€118M by 2030); the multi-billion exit thesis depends on aortic expansion, where the company is at proof-of-concept stage, not in clinical study.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">SAM figures in the platform analysis do not add up arithmetically: €3.2B pulmonary plus €7.1B aortic is stated as a combined SAM of €3.5B — methodological sloppiness.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Market-share ambitions stated in the investor call (5% of aortic, 30–50% of pediatric pulmonary) are aggressive and are not built into the formal revenue projections.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Aortic-regurgitation segment is becoming consolidated (Edwards acquiring both JenaValve and JC Medical in 2024); competitive intensity is increasing rapidly, and the JenaValve transaction is under FTC challenge as of August 2025.</span></span></span></li> </ul> </td> </tr> </tbody> </table> <h3><span style="font-size:12pt"><span style="font-family:"Times New Roman",serif"><span style="color:#1f4d78">Business model</span></span></span></h3> <table cellspacing="0" class="Table" style="border-collapse:collapse; border-color:currentcolor; border-image:initial; border-style:none; border-width:medium"> <tbody> <tr> <td style="background-color:#faeeda; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:624px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Score 62 of 100</span></strong><span style="color:black"> — Moderate. Data quality: MODERATE.</span></span></span></p> </td> </tr> </tbody> </table> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">The company reports three revenue streams: procedure-pack sales (the main product, MDR Class III), on-site service in the operating room, and physician training and licensing. The cost position is structurally advantaged — the company states cost of goods sold at approximately €1,000 per pack versus sale prices of €8,000–€16,000 for incumbent animal-tissue valves. Projected revenue ramps from €7.9M in 2030 to €176.5M in 2035 with gross margin from 63% to 87%. Final pricing has not been negotiated with any payer.</span></span></p> <table cellspacing="0" class="Table" style="border-collapse:collapse; border-color:currentcolor; border-image:initial; border-style:none; border-width:medium"> <thead> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:312px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black"><strong><span style="font-family:"Arial Unicode MS"">✅ Strengths</span></strong></span></span></span></p> </td> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:312px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">⚠️ Gaps</span></strong></span></span></p> </td> </tr> </thead> <tbody> <tr> <td style="border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:312px"> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Three articulated revenue streams (procedure-pack sales, on-site service, physician training and licensing) capture multiple parts of the value chain.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Cost position is structurally advantaged: ~€1,000 COGS per pack versus €8,000–€16,000 sale price for animal-tissue valves.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Gross-margin trajectory from 63% (2030) to 87% (2035) is consistent with consumables medtech businesses at scale, if volume materialises.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Procedure-pack model is capital-light versus the centralised manufacturing of incumbents — meaningful working-capital and inventory advantages.</span></span></span></li> </ul> </td> <td style="border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:312px"> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Final pricing is not disclosed; the entire revenue projection rests on a per-valve sale price that has not been negotiated with any payer.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">2030 revenue projection of €7.9M assumes EU and US approval are achieved that year and ramp begins immediately — both extremely optimistic given the company's own "about 3.5 years to broad approval" SWOT acknowledgment.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Selling 1,000+ valves in year one of approval is a stretch goal; the "tsunami of valve re-do" narrative supports demand but does not solve clinical-adoption pacing or centre-of-excellence build-out.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Revenue concentration: aortic projected to be 81–87% of revenue across the projection window, but the aortic programme is materially earlier in development than the pulmonary programme.</span></span></span></li> </ul> </td> </tr> </tbody> </table> <h3><span style="font-size:12pt"><span style="font-family:"Times New Roman",serif"><span style="color:#1f4d78">Competition</span></span></span></h3> <table cellspacing="0" class="Table" style="border-collapse:collapse; border-color:currentcolor; border-image:initial; border-style:none; border-width:medium"> <tbody> <tr> <td style="background-color:#faeeda; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:624px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Score 65 of 100</span></strong><span style="color:black"> — Moderate. Data quality: MODERATE.</span></span></span></p> </td> </tr> </tbody> </table> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Direct competitors (Medtronic Melody and Harmony, Edwards SAPIEN 3 Pulmonic and Alterra) are accurately profiled in the deck with materials, indications and structural differences clearly stated. The differentiation thesis — personalized autologous tissue with a bioabsorbable stent versus permanent foreign tissue in a metal frame — is genuinely substantive. IP coverage spans the full procedure stack across three patent families filed 2014–2021, with one US patent granted January 2024 and the rest in pendency.</span></span></p> <table cellspacing="0" class="Table" style="border-collapse:collapse; border-color:currentcolor; border-image:initial; border-style:none; border-width:medium"> <thead> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:312px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black"><strong><span style="font-family:"Arial Unicode MS"">✅ Strengths</span></strong></span></span></span></p> </td> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:312px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">⚠️ Risks</span></strong></span></span></p> </td> </tr> </thead> <tbody> <tr> <td style="border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:312px"> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Direct competitors are accurately profiled with materials, indications and structural differences clearly stated.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Differentiation thesis (personalized autologous tissue plus bioabsorbable stent) is genuinely substantive, not cosmetic.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">IP coverage spans the full procedure stack: imaging-to-mould, tissue shaping, crosslinking and implantation — three patent families filed 2014–2021, one US patent granted January 2024.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">CTO states 5–7 year replication moat for any competitor starting from zero — driven by the database build-out a competitor would need for approval.</span></span></span></li> </ul> </td> <td style="border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:312px"> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">The deck competition table omits Xeltis (a bioabsorbable-polymer-scaffold valve in clinical development, where CTO Warnack previously worked) and the Ozaki autologous-pericardium surgical procedure — both materially closer competitors on the regenerative thesis than the listed bioprosthesis incumbents.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Only one patent family has been granted (US, January 2024); the other two are still in pendency across jurisdictions, with grant outcomes uncertain.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Freedom-to-Operate analysis is self-reported as completed by external counsel with no infringements found, but is not independently verifiable in the provided materials.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Strategic incumbents (Medtronic, Edwards, Boston Scientific) have R&D budgets that dwarf GrOwnValve's; a buy-versus-build decision can pivot rapidly based on early clinical data.</span></span></span></li> </ul> </td> </tr> </tbody> </table> <h3><span style="font-size:12pt"><span style="font-family:"Times New Roman",serif"><span style="color:#1f4d78">Compliance & regulatory</span></span></span></h3> <table cellspacing="0" class="Table" style="border-collapse:collapse; border-color:currentcolor; border-image:initial; border-style:none; border-width:medium"> <tbody> <tr> <td style="background-color:#faeeda; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:624px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Score 60 of 100</span></strong><span style="color:black"> — Moderate. Data quality: MODERATE.</span></span></span></p> </td> </tr> </tbody> </table> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">MDR Class III is the correct route for the device class, and BfArM has confirmed the regulatory pathway via a scope-of-application procedure — the classification is not contested. The FDA dialogue is active with Breakthrough Device Designation pathway under discussion; if granted, this would meaningfully compress US review timelines. About 3.5 years to broad market approval per the company's own SWOT, with autologous-tissue MDR pathway having limited precedent.</span></span></p> <table cellspacing="0" class="Table" style="border-collapse:collapse; border-color:currentcolor; border-image:initial; border-style:none; border-width:medium"> <thead> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:312px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black"><strong><span style="font-family:"Arial Unicode MS"">✅ Strengths</span></strong></span></span></span></p> </td> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:312px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">⚠️ Gaps</span></strong></span></span></p> </td> </tr> </thead> <tbody> <tr> <td style="border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:312px"> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">ISO 13485 certification completed at the end of 2025 — a meaningful operational achievement at this stage.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">BfArM (Germany) has confirmed the MDR Class III pathway via a scope-of-application procedure; classification is not contested.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">FDA dialogue is active with Breakthrough Device Designation pathway under discussion; if granted, would compress US review timelines.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Post-Market Surveillance system established; ISO/ASTM 52920:2023 qualification completed for the additive-manufacturing process used for the patient-specific mould.</span></span></span></li> </ul> </td> <td style="border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:312px"> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">About 3.5 years to broad market approval per the company's own SWOT — a long and capital-intensive bridge during which a clinical setback could materially reset the timeline.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">MDR Class III approvals for novel autologous-tissue devices have limited precedent; Notified Body cycles and the Clinical Evaluation Consultation Procedure can be slow.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Point-of-care manufacturing model is regulatorily novel; quality-control expectations for the in-operating-room portion of value creation are not fully settled in either MDR or FDA frameworks.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Pediatric approval — the segment with the strongest marketing emphasis — is contingent on a separate clinical study plus an adolescent-feasibility study, with earliest realistic approval in 2031+.</span></span></span></li> </ul> </td> </tr> </tbody> </table> <h3><span style="font-size:12pt"><span style="font-family:"Times New Roman",serif"><span style="color:#1f4d78">Technology risk</span></span></span></h3> <table cellspacing="0" class="Table" style="border-collapse:collapse; border-color:currentcolor; border-image:initial; border-style:none; border-width:medium"> <tbody> <tr> <td style="background-color:#faeeda; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:624px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Score 65 of 100</span></strong><span style="color:black"> — Moderate. Data quality: MODERATE.</span></span></span></p> </td> </tr> </tbody> </table> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Preclinical evidence is unusually strong: 21-month follow-up in 29 sheep showed no calcification, no degeneration, no stenosis and complete endothelialization, published in a peer-reviewed cardiology journal. Procedure complexity (about 1.5 hours intervention, 4–5 hours total in operating room) is comparable to existing TAVR procedures performed thousands of times daily worldwide. The bioresorbable pediatric stent — the technical foundation of the child-specific value proposition — is still in development, not in human clinical study. A meaningful portion of value creation happens in the operating room, introducing inter-surgeon variability that has not been industrially de-risked at scale.</span></span></p> <table cellspacing="0" class="Table" style="border-collapse:collapse; border-color:currentcolor; border-image:initial; border-style:none; border-width:medium"> <thead> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:312px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black"><strong><span style="font-family:"Arial Unicode MS"">✅ Strengths</span></strong></span></span></span></p> </td> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:312px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">⚠️ Risks</span></strong></span></span></p> </td> </tr> </thead> <tbody> <tr> <td style="border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:312px"> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">21-month sheep follow-up in 29 animals shows no calcification, no degeneration, no stenosis and complete endothelialization; native-like remodelling on histology (Kiekenap et al. 2024).</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">IP coverage across the full procedure stack — three patent families spanning imaging-to-mould, tissue shaping, crosslinking and implantation, plus the proprietary glutaraldehyde-free crosslinker.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Procedure complexity is comparable to existing TAVR procedures already performed thousands of times daily worldwide.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Initial bioresorbable-stent implantation in a sheep model has been demonstrated, supporting the pediatric path; ISO/ASTM 52920 qualification on 3D-printing process is in place.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Cost structure (~€1,000 per procedure pack vs €8,000–€16,000 for centrally manufactured animal-tissue valves) is structurally large.</span></span></span></li> </ul> </td> <td style="border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:312px"> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Operator-dependence is real: a meaningful portion of value creation (tissue shaping, suturing, crosslinking) happens in the operating room rather than in a factory; inter-surgeon variability has not been industrially de-risked at scale.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Bioresorbable pediatric stent — the technical foundation of the child-specific value proposition — is still in development, not in human clinical study.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Design freeze for core components is targeted for late 2026 to early 2027; the device is not yet final.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Scaling from 5 valves implanted (feasibility study) to approximately 1,000 valves per year (2030 revenue projection) is a roughly 200× volume jump in 4 years; supply-chain, training and operator-variability questions are all open.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Only one patent family granted; remaining IP protection is contingent on prosecution outcomes across jurisdictions.</span></span></span></li> </ul> </td> </tr> </tbody> </table> <p> </p> <h2><span style="font-size:13pt"><span style="font-family:"Times New Roman",serif"><span style="color:#2e74b5">🚩 Red flags & integrity checks</span></span></span></h2> <table cellspacing="0" class="Table" style="border-collapse:collapse; border-color:currentcolor; border-image:initial; border-style:none; border-width:medium"> <tbody> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:40px"> <p style="text-align:center"><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">1</span></strong></span></span></p> </td> <td style="border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:1px solid #bfbfbf; vertical-align:top; width:584px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong>Missing critical data</strong> — Liquidation preference, drag-along threshold, anti-dilution provisions, EIB instrument structure (debt/equity/quasi-equity), angel convertible-loan conversion terms (cap/discount/trigger), founder vesting and ESOP size are all undisclosed. For a profit-participating right behind multiple senior tranches in a binary-outcome medtech, these are central to the actual economics.</span></span></p> </td> </tr> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:40px"> <p style="text-align:center"><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">2</span></strong></span></span></p> </td> <td style="border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:584px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong>Internal inconsistencies</strong> — Round size is disclosed inconsistently: deck says €12M total with ~€4.5M open; the April 2026 investor call says €6.2M total with €1.5M open via Companisto. Patient implant counts vary (4 in deck, 5 in analysis and investor call). Team size appears as 15, 18 and 22 across the same package. Total funding raised since 2019 appears as €5.5M+, €7.8M and €8M in different places. The 2030 revenue projection assumes EU and US approval in the same year, inconsistent with the company's own "about 3.5 years to broad approval" SWOT.</span></span></p> </td> </tr> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:40px"> <p style="text-align:center"><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">3</span></strong></span></span></p> </td> <td style="border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:584px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong>External discrepancies</strong> — DHZC's official press release of 19 June 2025 announced the first implantation, but the deck and analysis both date the first operation to February 2025 — the 4-month gap is unexplained (possibly a deliberate safety-window delay before publication). Older Charité communications referred to compassionate-use cases in India in 2016, while company materials describe them as 2017 — a one-year date drift. JenaValve, the most recent and largest reference exit cited in the deck, is under FTC challenge as of August 2025; the deck does not mention this.</span></span></p> </td> </tr> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:40px"> <p style="text-align:center"><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">4</span></strong></span></span></p> </td> <td style="border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:584px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong>Negative public information</strong> — None found in public registries or news searches. No founder controversy, dismissal or governance breakdown was surfaced. The clinical-trial registration on ClinicalTrials.gov is in good standing and recruiting. No active litigation surfaced.</span></span></p> </td> </tr> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:40px"> <p style="text-align:center"><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">5</span></strong></span></span></p> </td> <td style="border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:584px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong>Prior fundraises</strong> — Total funding since 2019 spin-off reported at €7.8M by DZHK. Composition: €3.1M EIC Accelerator (grant + equity), €2.5M EIC Transition, plus various exist, Spark, BMBF and BIH programmes adding to €5.5M+ in non-dilutive grants; plus approximately €1.3M from angels and family offices. Milestones broadly met since prior funding: clinical trial started, ISO 13485 achieved, first-in-human implants performed, peer-reviewed publication delivered. The round-size disclosure inconsistency in #2 is the principal caveat.</span></span></p> </td> </tr> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #bfbfbf; border-left:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:40px"> <p style="text-align:center"><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">6</span></strong></span></span></p> </td> <td style="border-bottom:1px solid #bfbfbf; border-left:none; border-right:1px solid #bfbfbf; border-top:none; vertical-align:top; width:584px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong>Valuation reasonableness</strong> — €18M pre-money is supported only by a list of 10 reference M&A transactions in structural-heart medtech (purchase prices $72M–$435M+); no DCF, no revenue multiple and no comparable-stage benchmarking is shown. The €18M figure reconciles mathematically to the disclosed cap-table arithmetic under the smaller round figure (€1.6M Companisto tranche giving 8.19% pool share = roughly €18M pre-money). On benchmarks: a clinical-feasibility-stage MDR Class III medtech with €5.5M+ in grants, an active first-in-human trial, ISO 13485 and a granted US patent typically prices between €10M and €25M pre-money on European platforms; €18M sits on the higher side of that median. The premium reflects clinical traction and market size, not commercial traction.</span></span></p> </td> </tr> </tbody> </table> <p> </p> <h2><span style="font-size:13pt"><span style="font-family:"Times New Roman",serif"><span style="color:#2e74b5">📝 Data quality notes</span></span></span></h2> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong>Categories scored N/A: </strong>None. All eight categories were evaluable; no weight redistribution was required.</span></span></p> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong>Categories with LIMITED data quality: </strong>Traction (capped at maximum score of 70). This reflects the pre-revenue status of the company — structural to the clinical-feasibility stage rather than a company-specific weakness. The traction that does exist (grant funding, active clinical trial, regulatory dialogue, publication record) is real and was scored on those inputs.</span></span></p> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Most material missing items that would change the evaluation if obtained:</span></span></p> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Liquidation-preference order and multiple, and how the EIB tranche and the angel convertible-loan agreement rank relative to the Companisto pool. This is the single most material gap — in any moderate or weak exit, this determines whether crowdfund investors receive anything.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Drag-along threshold and tag-along rights. Without these, the crowdfund pool's leverage in an exit negotiation cannot be assessed.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Reconciled round size — the €12M-vs-€6.2M discrepancy needs to be resolved before any investor can know what fraction of the company they are buying at the stated valuation.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Full GECT-DZHK28 study read-out at the planned 6–12 month endpoint for all 7 patients. Until this is in hand, the company's primary clinical-evidence thesis remains preliminary.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Pediatric clinical data. The marketing emphasis is on pediatrics; the clinical evidence to date is in adults. Adolescent-feasibility data (planned 2028–2029) is the next major value-affecting milestone.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">EIB instrument structure — debt, equity or quasi-equity. This determines whether the EIB tranche dilutes the crowdfund pool or stands ahead of it in liquidation.</span></span></span></li> </ul> <p> </p> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><em>Memo generated by AI from public information and platform-disclosed company materials. Investors must perform their own due diligence. Past fundraising or operational performance does not guarantee future results. Crowdfunding investments are illiquid, high-risk, and capital loss is possible.</em></span></span></p>
See full overview
Ask question
Ask AI about this project
Beta
Start a conversation
Send a message to begin chatting with the AI assistant
Like this project?
Platform offering this project
Companisto DE
Risk Level
High
Risk Return Level
Medium
Return Level
High
Min. Investment
EUR 250
Total Funded
EUR 228.78M
